Myopia Induced after Systemic Chemotherapy with Docetaxel
Journal of Ophthalmic and Optometric Sciences,
Vol. 8 No. 4 (2024),
22 September 2024
,
Page 38-42
https://doi.org/10.22037/joos.v8i4.48648
Abstract
Transient myopia is an unreported toxicity of docetaxel. We report an unexpected development of myopia following systemic chemotherapy with docetaxel. A 38-year-old woman undergoing chemotherapy for breast cancer received docetaxel every two weeks. Prior to chemotherapy, she had no visual impairments, ocular disorders, or other comorbidities. After seven cycles of systemic chemotherapy, she began experiencing visual impairment. Her spherical equivalent refractive errors were -2.00 D in the right eye and -1.63 D in the left eye. Uncorrected visual acuity was 0.42 logMAR in the right eye and 0.3 logMAR in the left eye, both correctable to 0 logMAR. At a 4-week follow-up after cessation of chemotherapy, her vision gradually recovered. To our knowledge this is the first reported case of docetaxel induced myopia in a patient undergoing cancer treatment in the English literature, underscoring the need for clinicians to be aware of this potential ocular toxicity.
- Breast Cancer
- Chemotherapy
- Myopia
- Docetaxel
- Visual Acuity
How to Cite
References
Wu PC, Huang HM, Yu HJ, Fang PC, Chen CT. Epidemiology of Myopia. Asia Pac J Ophthalmol (Phila). 2016;5(6):386-93.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.
Kroschinsky F, Stölzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21(1):89.
Esmaeli B, Burnstine MA, Ahmadi MA, Prieto VG. Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa. Ophthalmic Plast Reconstr Surg. 2003;19(4):305-8.
Tsalic M, Gilboa M, Visel B, Miller B, Haim N. Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity. Med Oncol. 2006;23(1):57-61.
Torrado LA, Fivgas GD. Unilateral cystoid macular edema and bilateral subfoveal hyperreflectivity following docetaxel chemotherapy: A case report. Am J Ophthalmol Case Rep. 2020;20:100995.
Kintzel PE, Michaud LB, Lange MK. Docetaxel-associated epiphora. Pharmacotherapy. 2006;26(6):853-67.
Teitelbaum BA, Tresley DJ. Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci. 2003;80(4):277-9.
Yuan X, Feng Y, Li D, Li M. Unilateral visual impairment in a patient undergoing chemotherapy: a case report and clinical findings. BMC Ophthalmol. 2019;19(1):236.
Kaimbo D. Transient Drug-Induced Myopia. SAJ Case Rep 2014;1(1):1-5.
Ikeda N, Ikeda T, Nagata M, Mimura O. Ciliochoroidal effusion syndrome induced by sulfa derivatives. Arch Ophthalmol. 2002;120(12):1775.
Ryan EH Jr, Jampol LM. Drug-induced acute transient myopia with retinal folds. Retina. 1986;6(4):220-3.
Sen HA, O'Halloran HS, Lee WB. Case reports and small case series: topiramate-induced acute myopia and retinal striae. Arch Ophthalmol. 2001;119(5):775-7.
- Abstract Viewed: 95 times
- pdf Downloaded: 72 times
